Evaxion Biotech A/S ADR (NASDAQ: EVAX) is -55.37% lower on its value in year-to-date trading and has touched a low of $2.26 and a high of $13.61 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EVAX stock was last observed hovering at around $2.83 in the last trading session, with the day’s gains setting it 0.23%.
Currently trading at $3.06, the stock is -2.19% and 2.87% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.78 million and changing 8.13% at the moment leaves the stock -24.26% off its SMA200. EVAX registered -61.27% loss for a year compared to 6-month gain of 2.00%. The firm has a 50-day simple moving average (SMA 50) of $2.97792 and a 200-day simple moving average (SMA200) of $4.020755.
The stock witnessed a -4.08% loss in the last 1 month and extending the period to 3 months gives it a 6.62%, and is -2.86% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.49% over the week and 9.83% over the month.
Evaxion Biotech A/S ADR (EVAX) has around 49 employees, a market worth around $16.55M and $0.28M in sales. Profit margin for the company is -5464.05%. Distance from 52-week low is 35.40% and -77.52% from its 52-week high. The company has generated returns on investments over the last 12 months (-135.02%).
Evaxion Biotech A/S ADR quarterly earnings per share for the current quarter are estimated at -0.31 with sales reaching $120k over the same period.The EPS is expected to grow by 90.25% this year
